{"DataElement":{"publicId":"4379843","version":"1","preferredName":"Contraception Agreement Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator relating to the patient's agreement to use effective contraception during protocol treatment.","longName":"CTCPT_AGR_COD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2014053","version":"1","preferredName":"Contraception Agreement","preferredDefinition":"the patient's agreement to use effective contraception during protocol treatment.","longName":"CONTRACEPTION_AGR","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2725194","version":"1","preferredName":"Contraception","preferredDefinition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","longName":"C37932","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contraception","conceptCode":"C37932","definition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"448E87D9-8E4A-47E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-25","modifiedBy":"ONEDATA","dateModified":"2008-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2520617","version":"1","preferredName":"Agreement","preferredDefinition":"1. The act of agreeing. 2. Harmony of opinion; accord. (from American Heritage Dictionary)","longName":"C25369","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agreement","conceptCode":"C25369","definition":"The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DFE6E80-0641-12A3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-21","endDate":null,"createdBy":"AYANLOWA","dateCreated":"2006-09-21","modifiedBy":"ONEDATA","dateModified":"2006-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008542","version":"1","preferredName":"Reproduction","preferredDefinition":"the patient's ability to conceive or nurse offspring and/or their current reproductive status.","longName":"REPRODUCTION","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227DAE6-EC15-4A7D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B318870A-C908-3702-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-31","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876423","version":"1","longName":"Consents & Contraceptive Guidelines","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"CTCPT_AGR_COD_IND","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient is male, does patient agree to use adequate contraception prior to study entry, for duration of study participation and for 1 month after completion of dabrafenib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If male, does patient  whose partners are pregnant or might be pregnant agree to use condoms for the duration of the study and for 4 months following completion of drug administration?","url":null,"context":"Theradex"},{"name":"Theradex-2","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 4 months after completion of gemcitabine and eribulin administration?","url":null,"context":"Theradex"},{"name":"Does male patient of fatherin","type":"Preferred Question Text","description":"Does male patient of fathering potential, agree to use an adequate method of contraception throughout the study and for up to 12 weeks after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 4 months after completion of TRC102, pemetrexed and cisplatin administration?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 4 months after completion of BMN 673 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does male patient agree to use condoms with spermicide, even after vasectomy, during sexual intercourse with female partner, while being treated with GDC-0449 and for 3 months after the last dose?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does male patient agree to use two forms of contraception prior to study entry, for duration of study participation, and for 31 weeks after last dose of nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 4 months after completion of MLN0128 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If male (including those that are vasectomized), does patient whose partners are pregnant or might be pregnant agree to use condoms for the duration of the study and for 6 months following completion of drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 4 months after completion of erlotinib and/or Onalespib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Does male patient agree to use 2 adequate methods of contraception starting with the screening visit, for the duration of study participation and through 120 days after the last dose of MK-3475?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 4 months after completion of nivolumab administration?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 4 months after completion of cediranib and olaparib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Does male patient agree to a latex condom, even after vasectomy, during sexual contact with female of child bearing potential?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Is male patient who is sexually active, willing and able to use a medically acceptable form of contraception throughout the study and for up to 6 months after completion of VX-970 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Does male patient also agree to use highly effective barrier contraception prior to study entry, for duration of study participation, and for 4 months after completion of MLN0128 (TAK-228) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Does male patient, even if surgically sterilized (i.e., status post-vasectomy) agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Does patient (men treated or enrolled on this protocol) agree to use adequate contraception and not to donate sperm prior to the study, for the duration of study participation, and for 3 months after completion of the study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 4 months after study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Does male patient, even if surgically sterilized (i.e., status postvasectomy), agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR  practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"If fertile, does male patient agree to use adequate contraceptive measures during and for 4 months after AZD9291 (osimertinib)?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does non-sterilized male patient who is sexually active with a female partner of childbearing potential agree to use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy and refrain from sperm donation throughout this period?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Does male patient, who is sexually active with woman of childbearing potential,  agree to use adequate contraception prior to study entry, for duration of study participation, and for 4 months after completion of entinostat and MK3475 (pembrolizumab) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 6 months after completion of cediranib and olaparib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 7 months after study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"If male (including those that are vasectomized), does patient whose partners are pregnant or might be pregnant agree to use condoms for the duration of the study and for 90 days following completion of drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"If female partner of male patient uses hormonal contraceptive, is partner on a stable dose of the same hormonal contraceptive product for at least 4 weeks before receiving study drug) AND is supplemented with a condom (hormonal contraceptives must be supplemented with condoms)?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception or complete abstinence prior to study entry, for duration of study participation, and for 5 months (150 days) after last dose of study agent?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does male patient and their female partners, who are sexually active and of childbearing potential, agree to the use of two highly effective forms of contraception in combination, and not to donate sperm, throughout the period of taking study treatment and for 3 months after last dose of study drug(s)?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Does male patient who is the partner of a woman of childbearing potential agree to use a condom and spermicide and their female partners if of childbearing potential must use a highly effective method of contraception beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 150 days after the last dose of study drug, unless the male subject is  totally sexually abstinent or has undergone a successful vasectomy with confirmed azospermia or unless the female partner(s) have been sterilized surgically or are otherwise proven sterile?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Is male patient willing to abstain or use barrier contraception (i.e., condoms) for the duration of the study and for 3 months after treatment stops?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Does male patient, treated or enrolled on this study, agree to use adequate contraception prior to the study, for the duration of study participation, and for 4 months after completion of AZD8186 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of MK-3475 (Pembrolizumab) in combination with KW-0761 (Mogamulizumab) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to study entry, for the duration of study participation, and for 7 months after completion of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Does patient agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of carboplatin and M6620 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Is male patient who is sexually active, willing and able to use a medically acceptable form of contraception throughout the study and for up to 6 months after completion of M6620 (VX-970) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"If fertile, is male patient willing to use barrier contraception during and for 4 months after AZD9291 (osimertinib)?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Does patient, men treated or enrolled on this protocol, agree to use adequate contraception prior to the study, during study participation and for 4 months after completion of veliparib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to the study, for duration of study participation and for 4 months after completion of MK3475 and ziv-afilbercept administration?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Does male patient receiving nivolumab who is sexually active with a woman of childbearing potential agree to adhere to contraception, with any contraceptive method with a failure rate of less than 1% per year, for a period of 7 months after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"If patient is male and is the sexual partner of a female of child-bearing potential, does patient agree to use any contraceptive method with a failure rate of less than 1% per year for the duration of study participation and for a period of 7 months after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"If patient is male, does patient agree to use adequate contraception prior to study entry, for duration of study participation and for 90 days after completion of pinometostat and azacitidine administration?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Does male patient, even if surgically sterilized, agree to practice effective barrier contraception during the entire study treatment period through 4 months after the last dose of study drug, or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Does male patient who is receiving nivolumab and is sexually active with a woman of childbearing potential, agree to use adequate contraception prior to study, during study participation, and will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Is male patient who is sexually active, willing and able to use a medically acceptable form of contraception throughout the study and for up to 6 months after completion of M6620 (VX-970) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Does male patient, even if surgically sterilized, agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of ixazomib and pevonedistat administration, OR practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Does male patient, even if surgically sterilized, agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of ixazomib and penovendistat administration, OR practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"If patient is male and is the sexual partner of a female of child-bearing potential, does patient agree to use a contraceptive method with a failure rate of less than 1% per year for the duration of study participation and for a period of 7 months after the last dose of nivolumab or ipilimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Does male patient, even if surgically sterile (i.e., status post vasectomy), agree to practice effective barrier contraception during the entire study treatment through 4 months after the last dose of study drug OR agrees to practice true abstinence if this is the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study, for duration of study participation and for 4 months after completion of CB-839 HCl administration?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"If patient is male and sexually active, patient agrees to use adequate contraception prior to study entry, for the duration of study participation and for 7 months after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Does male patient, even if surgically sterile (i.e., status post vasectomy), agree to practice effective barrier contraception during the entire study treatment through 4 months after the last dose of study drug OR agrees to practice true abstinence if this is the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Does patient planning to conceive or father children agree to use adequate contraception prior to study entry, during study participation and for 120 days after the last dose of study agent(s)?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception for 4 months after completion of CB-839 HCl (telaglenastat) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Does male patient, treated or enrolled on this this study, agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of copanlisib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Does male patient and their partner, who are sexually active and of childbearing potential, agree to the use of two highly effective forms of contraception in combination, throughout the period of taking study treatment and for 6 months after last dose of study drug(s) to prevent pregnancy in a partner?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"Does male patient with female partner of child-bearing potential agree to use one of following contraceptive methods:  Vasectomy with documentation of azoospermia OR Condom use PLUS partner use of a highly effective contraceptive (less than or equal to 1% rate of failure per year) such as intrauterine device or system, or hormonal birth control such as contraceptive subdermal implant, combined estrogen and progestogen oral contraceptive, injectable progestogen, contraceptive vaginal ring, or percutaneous contraceptive patches?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Does male patient, treated or enrolled on this this study, agree to use adequate contraception and not donate sperm prior to the study, for the duration of study participation, and 6 months after completion of Radium-223 dichloride?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Does patient agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of Radium-223 dichloride, M3814, and avelumab administration?","url":null,"context":"Theradex"},{"name":"Therdex - 61","type":"Alternate Question Text","description":"Does patient, men treated or enrolled on this protocol agree to use adequate contraception prior to the study, during study participation and for 4 months after completion of MLN4924 (pevonedistat) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Does male patient with female partner of child-bearing potential agree to use a latex condom during sexual contact, even if they have had a successful vasectomy?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Does male patient, treated or enrolled on this study, agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of M6620 (VX-970) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"Does male patient agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agrees to refrain from donating sperm, for the duration of the study?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Does male patient agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agrees to refrain from donating sperm, for the duration of the study and for 28 days following the last dose of tocilizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Does male patient, treated or enrolled on this this protocol, agree to use adequate contraception prior to the study, for the duration of study participation, and 3.5 months after completion of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception for the duration of study participation and for 3 months after completion of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 72","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation, and for 7 months after the last dose of nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"If patient is male, does he agree to use adequate contraception prior to the study, for the duration of study participation and for 4 months after completion of IPdR administration?","url":null,"context":"Theradex"},{"name":"Theradex - 74","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol who is sexually active with women of childbearing potential or whose partner is pregnant and who has not had a vasectomy, agrees to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of Hu5F9-G4 (magrolimab) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 73","type":"Alternate Question Text","description":"If patient is male and is the sexual partner of a female of child-bearing potential, does patient agree to use a contraceptive method with a failure rate of less than 1% per year for the duration of study participation and for a period of 7 months after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 75","type":"Alternate Question Text","description":"Does male patient, with female partners of reproductive potential and pregnant partners who are treated or enrolled on this study, agree to use adequate contraception for the duration of study participation, for at least 4 months after completion of talazoparib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 78","type":"Alternate Question Text","description":"If patient is male and is sexually active with a woman of child-bearing potential, does patient agree to use any contraceptive method with a failure rate of less than 1% per year?","url":null,"context":"Theradex"},{"name":"Theradex - 79","type":"Alternate Question Text","description":"Does male patient assigned at birth agree to use a latex condom during penetrative vaginal intercourse with a PCBP even if they have had a vasectomy?","url":null,"context":"Theradex"},{"name":"Theradex - 76","type":"Alternate Question Text","description":"If the patient is male, does the patient agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of DS-8201a and olaparib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 77","type":"Alternate Question Text","description":"Does the male patient with a female partner agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after the completion of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 82","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of venetoclax and ASTX727 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 80","type":"Alternate Question Text","description":"Is male patient who is sexually active with a woman of childbearing potential and who have not had a vasectomy, willing to use a barrier method of contraception (condom plus spermicidal gel) and refrain from sperm donation during the study and for 4 months after the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 84","type":"Alternate Question Text","description":"Is male patient who is sexually active, willing and able to use a medically acceptable form of contraception throughout the study and for up to 6 months after completion of M6620 (VX-970, berzosertib) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 86","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to the study, for the duration of study participation, and 5 months (150 days) after completion of atezolizumab, cobimetinib, and CDX-1127 (varlilumab) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 81","type":"Alternate Question Text","description":"Does male patient, even if surgically sterilized (i.e., status post vasectomy) agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for the duration of the study and for 3 months after completion of belinostat and SGI-110 (guadecitabine) or ASTX727 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 85","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to the study, for the duration of study participation, and 5 months after completion of erdafitinib and enfortumab vedotin administration?","url":null,"context":"Theradex"},{"name":"Theradex - 83","type":"Alternate Question Text","description":"Does male patient, treated or enrolled on this study, agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of M6620 (VX-970, berzosertib) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 87","type":"Alternate Question Text","description":"Does male patient with female partner of child-bearing potential agree to use one of following contraceptive methods:  Vasectomy with documentation of azoospermia OR Condom use PLUS partner use of a highly effective contraceptive (less than or equal to 1% rate of failure per year) such as intrauterine device or system, or hormonal birth control such as contraceptive subdermal implant, combined estrogen and progestogen oral contraceptive, injectable progestogen, contraceptive vaginal ring, or percutaneous contraceptive patches?","url":null,"context":"Theradex"},{"name":"Theradex - 91","type":"Alternate Question Text","description":"Does male patient agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agree to refrain from donating sperm during the treatment period and for 28 days after the last dose of ipatasertib?","url":null,"context":"Theradex"},{"name":"Theradex - 88","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agrees to use adequate contraception (latex or synthetic condom or abstinence) prior to the study, for the duration of study participation, and 3 months after completion of Venetoclax and ASTX727 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 89","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol also agree to use adequate contraception prior to the study, for the duration of study participation, and 7 months after completion of study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception for 4 months after completion of telaglenastat (CB-839) HCl administration?","url":null,"context":"Theradex"},{"name":"Theradex - 90","type":"Alternate Question Text","description":"Does male patient agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and also agrees to refrain from donating sperm during the treatment period, and for 5 months after the last dose of pembrolizumab and 28 days after the last dose of ipatasertib?","url":null,"context":"Theradex"},{"name":"Theradex - 92","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to study entry, for duration of study participation and for 3 months after completion of dasatinib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 95","type":"Alternate Question Text","description":"If patient is male and is the sexual partner of a female of child-bearing potential, does patient agree to use any contraceptive method with a failure rate of less than 1% per year and agrees to highly-effective contraceptive measures of birth control and not to father a child while receiving treatment and for a period of 3 months after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 93","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of durvalumab administration, if having sex with women of childbearing potential?","url":null,"context":"Theradex"},{"name":"Theradex - 96","type":"Alternate Question Text","description":"Does patient, men whose partners are or become pregnant, agree to use condoms for 12 weeks after the last dose of study medication?","url":null,"context":"Theradex"},{"name":"Theradex - 94","type":"Alternate Question Text","description":"Does male patient, treated or enrolled on this protocol, agree to use adequate contraception prior to the study, for the duration of study participation, for 3 months after the last dose of neratinib, or 4 months after completion of DS-8021a administration, whichever is longer?","url":null,"context":"Theradex"},{"name":"Theradex - 97","type":"Alternate Question Text","description":"Does male patient, treated or enrolled on this study, agree to use adequate contraception prior to the study, for the duration of study participation, and 7 months after completion of study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 98","type":"Alternate Question Text","description":"Does male patient, treated or enrolled on this protocol, agree to use adequate contraception prior to the study, for the duration of study participation, and 90 days after completion of study treatment administration?","url":null,"context":"Theradex"},{"name":"Theradex - 99","type":"Alternate Question Text","description":"Does male participant and their female partners agree to use adequate contraception (prior to study entry and for the duration of study participation and for 4 months after completion of Lutetium Lu 177 dotatate administration?","url":null,"context":"Theradex"},{"name":"Theradex - 100","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of ZEN003694 (ZEN-3694), MK-3475 and nab-Paclitaxel administration?","url":null,"context":"Theradex"},{"name":"Theradex - 101","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of tazemetostat and belinostat administration?","url":null,"context":"Theradex"},{"name":"Theradex - 102","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to the study, for the duration of study participation, and 90 days after completion of CA-4948, nab-paclitaxel, and gemcitabine administration?","url":null,"context":"Theradex"},{"name":"Theradex - 103","type":"Alternate Question Text","description":"Does patient, men treated or enrolled on this protocol, agree to use adequate contraception prior to the study, during study participation and for 4 months after completion of Lutetium Lu 177 dotatate and sunitinib malate administration?","url":null,"context":"Theradex"},{"name":"Theradex - 104","type":"Alternate Question Text","description":"Does male patient of reproductive potential agree to use an adequate method of contraception while receiving study drug and for 3 months after the last dose of study drug by complying with methods of contraception as outlined in Section 6.6 (Contraception and Pregnancy)?","url":null,"context":"Theradex"},{"name":"Theradex - 105","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agrees to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of M1774 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 106","type":"Alternate Question Text","description":"Does patient, treated or enrolled on this protocol, agree to use adequate contraception prior to the study, for the duration of study participation, and 7 days after completion of darolutamide administration or after the depot interval for the leuprolide-acetate dose used has been completed, whichever is longer?","url":null,"context":"Theradex"},{"name":"Theradex - 107","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to the study, for the duration of study participation, and for 2 weeks after completion of APG-1252 and cobimetinib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 108","type":"Alternate Question Text","description":"Does male patient who is sexually active with women of child-bearing potential (WOCBP) agree to use any contraceptive method with a failure rate of less than 1% per year?","url":null,"context":"Theradex"},{"name":"Theradex - 109","type":"Alternate Question Text","description":"Does male patient of fathering potential, having intercourse with females of childbearing potential agrees to abstain from heterosexual intercourse or have their partner use 2 forms of contraception from screening visit until 120 days until the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 110","type":"Alternate Question Text","description":"Does male patient treated or enrolled on this protocol agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of M1774 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 111","type":"Alternate Question Text","description":"Does male patient agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of M1774 and avelumab administration?","url":null,"context":"Theradex"},{"name":"Theradex - 112","type":"Alternate Question Text","description":"Does male patient with female partner of childbearing potential, agree to use adequate contraception (abstain or condom) and refrain from donating sperm for the duration of study participation, 5 months after the final dose of polatuzumab vedotin, and 1 month after the last dose of lenalidomide?","url":null,"context":"Theradex"},{"name":"Theradex - 113","type":"Alternate Question Text","description":"Does male patient, even if they have undergone a successful vasectomy. who is sexually active with FCBP agrees to use a latex or synthetic condom while taking lenalidomide, during dose interruptions and for up to 4 weeks after discontinuing lenalidomide?","url":null,"context":"Theradex"},{"name":"Theradex - 114","type":"Alternate Question Text","description":"Does male patient who is sexually active with FCBP agree to use a latex or synthetic condom while taking lenalidomide, during dose interruptions and for up to 4 weeks after discontinuing lenalidomide, even if they have undergone a successful vasectomy?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3B5F10-789F-5EEF-E040-BB89AD4330C9","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-18","changeDescription":"2020-7-27 AQT added for protocol 10389. AK Theradex_ghd_07-02-14","administrativeNotes":"6/23/23 Added AQT for Theradex ticket number CADSR0002547 cjl.","unresolvedIssues":null,"deletedIndicator":"No"}}